Additional file 2: Figure S2. of Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production

Immunoglobulin production of WT and IL-22−/− mice. Levels of total IgG (A) and IgG2a (B) antibodies against mBSA in the sera of WT and IL-22−/− mBSA-immunized mice. Data are the means ± SEM (n = 5). (TIFF 1185 kb

Additional file 4: Figure S4. of Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production

The inflammasome adapter ASC participates in articular hypernociception and neutrophil migration that are induced by IL-22 during AIA. (A) The concentrations of IL-1β in the knee joint injected with 1 ng of IL-22 or saline and pretreated with fucoidin (20 mg/kg, i.v. 15 min before stimuli injection) in mBSA-immunized mice were determined 3 h after the challenge. (B) Articular hypernociception was evaluated 1–7 h after i.a. injection with either IL-22 (1 ng per joint) or saline in mBSA-immunized WT or ASC−/− mice. (C) Neutrophil recruitment toward the articular cavity 7 h after i.a. administration of IL-22 (1 ng) or saline in mBSA-immunized WT or ASC−/− mice. Data are presented as the means ± SEM (n = 5). * P < 0.05, compared with the saline group; and # P < 0.05, compared with the vehicle (−)/WT IL-22 groups. (TIFF 930 kb

Additional file 3: Figure S3. of Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production

Role of IL-22 in zymosan-induced arthritis. (A and B) WT or IL-22−/− mice were challenged i.a. with zymosan (30 μg per joint) or saline and articular hypernociception (A) and neutrophil migration (B) were evaluated 7 h after the challenge. Data are presented as the means ± SEM (n = 5). * P < 0.05, compared with the saline group. (TIFF 1105 kb

Additional file 1: Figure S1. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis

Mean concentration–time profiles of lapachol after (A) 2 mg/kg i.v., (B) 10 mg/kg oral, and (C) 25 mg/kg oral administration to rats. Data points are mean ± standard deviation. (PDF 146 kb

Additional file 2: TableS1. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis

LAP and LAP sodium salt pharmacokinetic parameters determined by noncompartmental and compartmental approaches after i.v. administration of 2 mg/kg in Wistar rats. (PDF 93 kb

Additional file 6: Figure S3. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis

Serum levels of GPT and AST in LAP-treated mice during CIA protocol. (PDF 518 kb

Additional file 5: Table S3. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis

Evaluation of the toxicity of lapachol in proliferating CD4 T cells. (PDF 224 kb

Additional file 4: Figure S2. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis

Superimposition of the crystallographic hDHODH inhibitor A771726 (PDB id:1D3H, carbon atoms in cyan) and the top-ranked docking solution (carbon atoms in yellow), inside the active site. (PDF 458 kb